Medical therapy in porotic patients

Interventional Neuroradiology of the Spine: Clinical Features, Diagnosis and Therapy

Volumn , Issue , 2013, Pages 117-130

  Colao, Annamaria ^a   Vuolo, Laura ^a   Rubino, Manila ^a   Somma, Carolina Di ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902524147     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-88-470-2790-9_10     Document Type: Chapter

References (20)

1. Russell RGG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733-759
2. Pazianas M, Epstein S, Zaidi M (2009) Evaluating the antifracture efficacy of bisphosphonates. Rev Recent Clin Trials 2:122-130
3. Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 4:1555-1565
4. Shannon J, Shannon J, Modelevsky S, Grippo AA (2011) Bisphosphonates and osteonecrosis of the jaw. J Am Geriatr Soc 12:2350-2355
5. Reginster JY, Kaufman JM, Goemaere S et al (2012) Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int 3:1115-1122
6. Cesareo R, Napolitano C, Iozzino M (2010) Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal. Int J Women’s Health 2:1-6
7. Kinyó À, Belso N, Nagy N et al (2011) Strontium ranelate-induced DRESS syndrome with persistent autoimmunehepatitis. Acta Derm Venereol 2:205-206.
8. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized Controlled Trial. JAMA 288:321-333
9. Holloway D (2010) Clinical update on hormone replacement therapy. Br J Nurs 8:496, 498-504
10. Deal CL, Draper MW (2006) Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis - a clinical update on efficacy and safety. Women’s Health (Lond) 2:199-210
11. Silverman SL, Chines AA, Kendler DL et al; Baze-doxifene Study Group (2012) Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteo-poros Int 23:351-363
12. Cummings SR, Ensrud K, Delmas PD et al; PEARL Study Investigators (2010) Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 362:686-696
13. Tsourdi E, Rachner TD, Rauner M, Hamann C, Hofbauer LC (2011) Denosumab for bone diseases: translating bone biology into targeted therapy. Eur J Endocrinol 6:833-840
14. Lewiecki EM (2011) Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis. Drug Healthc Patient Saf 3:79-91
15. Han SL, Wan SL (2012) Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials. Int J Clin Pract 2:199-209
16. Pietrogrande L (2010) Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis. Int J Women’s Health 1:193-203
17. Carpinteri R, Porcelli T, Mejia C, Patelli I, Bilezikian JP, Canalis E, Angeli A, Giustina A, Mazziotti G (2010) Glucocorticoid-induced osteoporosis and parathyroid hormone. J Endocrinol Invest 33 (7 Suppl):16-21
18. Sikon A, Batur P (2010) Profile of teriparatide in the management of postmenopausal osteoporosis. Int J Women’s Health 2:37-44
19. Canalis E (2010) New treatment modalities in osteoporosis. Endocr Pract 5:855-863
20. Adami S, Bertoldo F, Brandi ML et al; Società Italiana dell’Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro (2009) Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo 4:260-284